In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus.
Int J Antimicrob Agents
; 20(1): 61-4, 2002 Jul.
Article
en En
| MEDLINE
| ID: mdl-12127713
ABSTRACT
The in vitro activity of levofloxacin, moxifloxacin, gatifloxacin, erythromycin, telithromycin, linezolid, synercid and vancomycin was measured against 36 genetically defined, gyrA/grlA double mutant MRSA clinical strains with an MIC to ciprofloxacin > or = 8 mg/l. The three newer fluoroquinolones tested were more active than ciprofloxacin. Resistance rates for levofloxacin and gatifloxacin were high (44.5 and 36.1%, respectively). All the strains were moxifloxacin-susceptible, though most of them had MICs close to the break point. All the strains were intermediate or resistant to erythromycin and most were also resistant to telithromycin. No strains were resistant to linezolid, synercid or vancomycin (MIC(90) 2, 1 and 2 mg/l, respectively).
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Staphylococcus aureus
/
Resistencia a la Meticilina
/
Macrólidos
/
Cetólidos
/
Antibacterianos
Idioma:
En
Revista:
Int J Antimicrob Agents
Año:
2002
Tipo del documento:
Article
País de afiliación:
España